Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chloramphenicol-induced bone marrow suppression

A A Yunis

    Seminars in Hematology
    |July 1, 1973
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Vitamin D3 and chemotherapy-induced alopecia.

    Nutrition (Burbank, Los Angeles County, Calif.)·1996
    Same author

    Familial infantile thrombotic thrombocytopenic purpura.

    Journal of pediatric hematology/oncology·1996
    Same author

    Pretreatment with 1,25(OH)2D3 protects from Cytoxan-induced alopecia without protecting the leukemic cells from Cytoxan.

    The American journal of the medical sciences·1995
    Same author

    Blood dyscrasias and topical ophthalmic chloramphenicol.

    American journal of ophthalmology·1993
    Same author

    Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3.

    Cancer research·1992
    Same author

    Protection from chemotherapy-induced neutropenia by ImuVert.

    The American journal of the medical sciences·1992
    Same journal

    The many facets of cardiopulmonary complications in sickle cell disease.

    Seminars in hematology·2026
    Same journal

    Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

    Seminars in hematology·2026
    Same journal

    Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

    Seminars in hematology·2026
    Same journal

    Telomeres biology disorders: the past, the present and the future.

    Seminars in hematology·2026
    Same journal

    Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

    Seminars in hematology·2026
    Same journal

    Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions.

    Seminars in hematology·2026
    See all related articles